Fairchild (Taiwan) Corp. v. Power Integrations, Inc.
Contributed by Schwegman Lundberg & Woessner. Originally published on Patexia; republished here as part of the LexDana archive.
In my last post, I discussed estoppel in the context in inter partes review, in which defendant filed for IPR after losing in the courts. The Board found the claims-in-suit to be obvious. The Federal Circuit affirmed that the courts and the PTAB could reach different conclusions about patentability.
In Fairchild (Appeal no. 17-1002 (Fed. Cir., April 21, 2017), the Federal Circuit found the asserted claims to be valid. Power Integrations had earlier filed for inter partes reexamination, using the same references it used in the District Court suit. The Federal Circuit ordered the PTAB to vacate and dismiss the reexamination of the claims found to be valid. Note that this decision rests on the provisions of 35 USC s. 317, which prevents a defendant that lost on invalidity in the courts from bringing the same challenge via inter partes reexamination. Section 317 (pre-AIA) is worded differently than Section 315(e)(2), relating to inter partes review estoppel. Post-AIA, defendant can lose at the district court but faces broad estoppel if it pursues IPR –although, (as in Novartis v. Noven) it can still prevail even if the records are identical (!) My head hurts!
This article was originally published on Patents4Life.com.
Patents4Life is sponsored by Schwegman Lundberg & Woessner, P.A.
More insights
Fresh From the Bench: Latest Precedential Patent Case
Ridge Corp. et al. v. Kirk NationaLease Co. et al. , Appeal No. 2025-1254 (Fed. Cir. July 13, 2026) In its only precedential patent opinion last week, the Federal Circuit considered an appeal of a preliminary injunction issued by the U.S. District Court…
Fresh From the Bench: Latest Precedential Patent Cases
CASE OF THE WEEK Wyeth LLC v. AstraZeneca Pharmaceuticals LP , Appeal No. 2024-2325 (Fed. Cir. July 9, 2026) In our Case of the Week, the Federal Circuit affirmed a district court ruling reversing a $107.5 million jury verdict against AstraZeneca in a case…
Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026)
CASE OF THE WEEK Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026) In our Case of the Week, the Federal Circuit affirmed summary judgment invalidating all claims of Enanta’s Patent No. 11,358,953 as…